touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab.
1. Why do chronic lymphocytic leukaemia (CLL) patients with alterations in the TP53 pathway represent an unmet clinical need? (0:10)
2. Could you tell us a little about venetoclax and its efficacy in CLL? (1:11)
3. What is the safety profile of venetoclax? (2:05)
4. What was the rationale for the investigation of the impact of clone size on outcomes in patients in the MURANO study? (2:56)
5. What were the findings of this investigation and what are the implications of these findings? (4:29)
Speaker disclosures: Arnon P Kater has nothing to disclose in relation to this video interview.
Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018.
Share this Video
Related Videos In Haematological Malignancies
Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma
We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]
Efstathios Kastritis, ASCO 2021: Results from the Phase 3 ANDROMEDA Study
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at ASCO 2021 to discuss the updated results from the phase 3 ANDROMEDA study. The abstract ‘Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results […]
Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML
touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!